{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:00:14Z","timestamp":1789210814719,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,7,4]],"date-time":"2006-07-04T00:00:00Z","timestamp":1151971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:p>Adaphostin is a tyrphostin that was designed to inhibit Bcr\/Abl tyrosine kinase by altering the binding site of peptide substrates rather than that of adenosine triphosphate, a known mechanism of imatinib mesylate (IM). However, it has been shown that adaphostin\u2010mediated cytotoxicity is dependent on oxidant production and does not require Bcr\/Abl. We have tested adaphostin against both Philadelphia chromosome (Ph)\u2010positive (K562, KBM5, KBM5\u2010R [IM resistant KBM5], KBM7, and KBM7\u2010R [IM\u2010resistant KBM7]) and Ph\u2010negative (OCI\/AML2 and OCI\/AML3) cells, and against cells from patients with chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Adaphostin significantly inhibited growth of all cell lines (50% inhibition of cell proliferation [IC<jats:sub>50<\/jats:sub>] 0.5\u20131\u00a0\u00b5M) except K562 (IC<jats:sub>50<\/jats:sub> 13\u00a0\u00b5M). Ph\u2010positive IM\u2010resistant cell lines showed significant cross resistance to adaphostin. Simultaneous or sequential treatment with adaphostin and IM did not exert a synergistic effect in any KBM line. Adaphostin induced superoxide and apoptosis in a dose\u2010dependent and time\u2010dependent fashion in both Ph\u2010positive and Ph\u2010negative cells. Adaphostin selectively inhibited colony growth of cells from CML (IM\u2010sensitive and IM\u2010resistant) and AML patients. Analysis of tyrosine phosphorylated proteins after treatment with adaphostin revealed alternate effects in different cells consistent with the modulation of multiple targets. In conclusion, adaphostin showed significant and selective activity against CML and AML cells and its development for clinical testing is warranted. (<jats:italic>Cancer Sci<\/jats:italic> 2006; 97: 952\u2013960)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2006.00269.x","type":"journal-article","created":{"date-parts":[[2006,7,5]],"date-time":"2006-07-05T23:00:04Z","timestamp":1152140404000},"page":"952-960","source":"Crossref","is-referenced-by-count":21,"title":["Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells"],"prefix":"10.1111","volume":"97","author":[{"given":"Nada","family":"Orsolic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Golemovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s\u2010Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taghi","family":"Manshouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Basic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,7,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907153410306"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2406902"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0596-561"},{"key":"e_1_2_5_5_2","first-page":"1661","article-title":"90\u00a0000 BCR\u2010ABL protein by a tyrosine kinase inhibitor (CGP\u201057148)","volume":"4","author":"Beran M","year":"1998","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3691"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90098-3"},{"key":"e_1_2_5_9_2","first-page":"1333","article-title":"The effect of imatinib mesylate on patients with Philadelphia chromosome\u2010positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Marcucci G","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10543"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199404000-00013"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199611000-00001"},{"key":"e_1_2_5_13_2","first-page":"237","article-title":"Effects of the bcr\/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro","volume":"6","author":"Svingen PA","year":"2000","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.664"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(98)00293-7"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00916-9"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0562"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207248"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2966"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2205"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2302"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.005"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207248"},{"key":"e_1_2_5_24_2","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM\u20105) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran M","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(87)90116-6"},{"key":"e_1_2_5_26_2","first-page":"264","article-title":"Expression of a retinioic acid receptor gene in myeloid leukemia cells","volume":"3","author":"Wang C","year":"1981","journal-title":"Leukemia"},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.V72.3.1029.bloodjournal7231029","article-title":"Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations","volume":"72","author":"Papayannopoulou T","year":"1988","journal-title":"Blood"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20131"},{"key":"e_1_2_5_29_2","first-page":"5995","article-title":"Mutation in the ATP\u2010binding pocket of the ABL kinase domain in an STI571\u2010resistant BCR\/ABL\u2010positive cell line","volume":"62","author":"Ricci C","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0507-6"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0668-y"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2006.00269.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2006.00269.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:31:59Z","timestamp":1697200319000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2006.00269.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,4]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1349-7006.2006.00269.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00269.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,4]]}}}